Literature DB >> 28586341

Erratum: Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease.

Nathaniel R West, Ahmed N Hegazy, Benjamin M J Owens, Samuel J Bullers, Bryan Linggi, Sofia Buonocore, Margherita Coccia, Dieter Görtz, Sébastien This, Krista Stockenhuber, Johanna Pott, Matthias Friedrich, Grigory Ryzhakov, Frédéric Baribaud, Carrie Brodmerkel, Constanze Cieluch, Nahid Rahman, Gerhard Müller-Newen, Raymond J Owens, Anja A Kühl, Kevin J Maloy, Scott E Plevy, Satish Keshav, Simon P L Travis, Fiona Powrie.   

Abstract

Entities:  

Year:  2017        PMID： 28586341     DOI： 10.1038/nm0617-788d

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  7 in total

1.  Biomarkers of Crohn's Disease to Support the Development of New Therapeutic Interventions.

Authors:  Amy C Porter; Jiri Aubrecht; Chandler Birch; Jonathan Braun; Carolyn Cuff; Suryasarathi Dasgupta; Jeremy D Gale; Robert Hinton; Steven C Hoffmann; Gerard Honig; Bryan Linggi; Marco Schito; Niels Vande Casteele; John-Michael Sauer
Journal:  Inflamm Bowel Dis       Date:  2020-09-18       Impact factor: 5.325

2.  Serum proteomic profiling at diagnosis predicts clinical course, and need for intensification of treatment in inflammatory bowel disease.

Authors:  R Kalla; A T Adams; D Bergemalm; S Vatn; N A Kennedy; P Ricanek; J Lindstrom; A Ocklind; F Hjelm; N T Ventham; G T Ho; C Petren; D Repsilber; J Söderholm; M Pierik; M D'Amato; F Gomollón; C Olbjorn; J Jahnsen; M H Vatn; J Halfvarson; J Satsangi
Journal:  J Crohns Colitis       Date:  2021-05-04       Impact factor: 10.020

Review 3.  New Frontiers in Genetics, Gut Microbiota, and Immunity: A Rosetta Stone for the Pathogenesis of Inflammatory Bowel Disease.

Authors:  Mingxia Zhou; Jing He; Yujie Shen; Cong Zhang; Jiazheng Wang; Yingwei Chen
Journal:  Biomed Res Int       Date:  2017-08-02       Impact factor: 3.411

4.  Putative biomarkers of vedolizumab resistance and underlying inflammatory pathways involved in IBD.

Authors:  Christoffer Soendergaard; Jakob Benedict Seidelin; Casper Steenholdt; Ole Haagen Nielsen
Journal:  BMJ Open Gastroenterol       Date:  2018-05-31

5.  Ileal Transcriptomic Analysis in Paediatric Crohn's Disease Reveals IL17- and NOD-signalling Expression Signatures in Treatment-naïve Patients and Identifies Epithelial Cells Driving Differentially Expressed Genes.

Authors:  James J Ashton; Konstantinos Boukas; James Davies; Imogen S Stafford; Andres F Vallejo; Rachel Haggarty; Tracy A F Coelho; Akshay Batra; Nadeem A Afzal; Bhumita Vadgama; Anthony P Williams; R Mark Beattie; Marta E Polak; Sarah Ennis
Journal:  J Crohns Colitis       Date:  2021-05-04       Impact factor: 9.071

Review 6.  Alterations and Potential Applications of Gut Microbiota in Biological Therapy for Inflammatory Bowel Diseases.

Authors:  Dan Pu; Zhe Zhang; Baisui Feng
Journal:  Front Pharmacol       Date:  2022-06-06       Impact factor: 5.988

7.  Cell-centred meta-analysis reveals baseline predictors of anti-TNFα non-response in biopsy and blood of patients with IBD.

Authors:  Renaud Gaujoux; Elina Starosvetsky; Naama Maimon; Yehuda Chowers; Purvesh Khatri; Shai S Shen-Orr; Francesco Vallania; Haggai Bar-Yoseph; Sigal Pressman; Roni Weisshof; Idan Goren; Keren Rabinowitz; Matti Waterman; Henit Yanai; Iris Dotan; Edmond Sabo
Journal:  Gut       Date:  2018-04-04       Impact factor: 23.059
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.